GnRH-II antagonists induce apoptosis in human endometrial, ovarian, and breast cancer cells via activation of stress-induced MAPKs p38 and JNK and proapoptotic protein bax

Cancer Research

Volumn 69, Issue 16, 2009, Pages 6473-6481

  Fister, Stefanie ^a   Günthert, Andreas R ^a   Aicher, Babette ^b   Paulini, Klaus W ^b   Emons, Günter ^a   Gründker, Carsten ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b Æterna Zentaris GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CETRORELIX; CYCLIC AMP; GONADORELIN AGONIST; GONADORELIN RECEPTOR; GONADOTROPIN RELEASING HORMONE 2 ANTAGONIST; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN BAX; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; DRUG RECEPTOR BINDING; ENDOMETRIUM CANCER; ENZYME ACTIVATION; FEMALE; GENE ACTIVATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; OVARY CANCER; PRIORITY JOURNAL; REPORTER GENE; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BREAST NEOPLASMS; ENDOMETRIAL NEOPLASMS; ENZYME ACTIVATION; FEMALE; GONADOTROPIN-RELEASING HORMONE; HORMONE ANTAGONISTS; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; OVARIAN NEOPLASMS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN BINDING; RECEPTORS, LHRH; TUMOR CELLS, CULTURED;

EID: 69249138652     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-4657     Document Type: Article

References (40)

1. Gründker C, Günthert AR, Westphalen S, Emons G. Biology of the gonadotropin-releasing hormone system in gynecological cancers. Eur J Endocrinol 2002; 146:1-14.
2. Emons G, Ortmann O, Becker M, et al. High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines. Cancer Res 1993;53:5439-46.
3. Emons G, Schröder B, Ortmann O, Westphalen S, Schulz KD, Schally AV. High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines. J Clin Endocrinol Metab 1993;77:1458-64.
4. Irmer G, Bürger C, Müller R, et al. Expression of the messenger RNAs for luteinizing hormone-releasing hormone (LHRH) and its receptor in human ovarian epithelial carcinoma. Cancer Res 1995;55:817-22.
5. Emons G, Ortmann O, Schulz KD, Schally AV. Growth inhibitory actions of luteinizing hormone-releasing hormone on tumor cells. Trends Endocrinol Metab 1997;8:355-62.
6. Gründker C, Günthert AR, Millar RP, Emons G. Expression of gonadotropin-releasing hormone II (GnRH-II) receptor in human endometrial and ovarian cancer cells and effects of GnRH-II on tumor cell proliferation. J Clin Endocrinol Metab 2002;87:1427-30.
7. Emons G, Müller V, Ortmann O, Schulz KD. Effects of LHRH-analogues on mitogenic signal transduction in cancer cells. J Steroid Biochem Mol Biol 1998;65: 199-206.
8. Gründker C, Völker P, Emons G. Antiproliferative signaling of luteinizing hormone-releasing hormone in human endometrial and ovarian cancer cells through G protein α(I)-mediated activation of phosphotyrosine phosphatase. Endocrinology 2001;142:2369-80.
9. Gründker C, Völker P, Schulz KD, Emons G. Luteinizing hormone-releasing hormone agonist Triptorelin and antagonist Cetrorelix inhibit EGF-induced c-fos expression in human gynecological cancers. Gynecol Oncol 2000;78:194-202.
10. Fister S, Günthert AR, Emons G, Gründker C. Gonadotropin-releasing hormone type II antagonists induce apoptotic cell death in human endometrial and ovarian cancer cells in vitro and in vivo. Cancer Res 2007;67:1750-6.
11. Beckers T, Marheineke K, Reilander H, Hilgard P. Selection and characterization of mammalian cell lines with stable over-expression of human pituitary receptors for gonadoliberin. Eur J Biochem 1995;231:535-43.
12. Kim BJ, Ryu SW, Song BJ. JNK- and p38 kinase-mediated phosphorylation of Bax leads to its activation and mitochondrial translocation and to apoptosis of human hepatoma HepG2 cells. J Biol Chem 2006;281: 21256-65.
13. Van Laethem A, Van Kelst S, Lippens S, et al. Activation of p38 MAPK is required for Bax translocation to mitochondria, cytochrome c release and apoptosis induced by UVB irradiation in human keratinocytes. FASEB J 2004;18:1946-8.
14. Lee HJ, Wang CJ, Kuo HC, Chou FP, Jean LF, Tseng TH. Induction apoptosis of luteolin in human hepatoma HepG2 cells involving mitochondria translocation of Bax/Bak and activation of JNK. Toxicol Appl Pharmacol 2005;203:124-31.
15. Harris CA, Johnson EM, Jr. BH3-only Bcl-2 family members are coordinately regulated by the JNK pathway and require Bax to induce apoptosis in neurons. J Biol Chem 2001;276:37754-60.
16. Gross A, Jockel J, Wei MC, Korsmeyer SJ. Enforced dimerization of BAX results in its translocation, mitochondrial dysfunction and apoptosis. EMBO J 1998;17:3878-85.
17. Salvesen GS, Renatus M. Apoptosome: the seven-spoked death machine. Dev Cell 2002;2:256-7.
18. Gogvadze V, Orrenius S, Zhivotovsky B. Multiple pathways of cytochrome c release from mitochondria in apoptosis. Biochim Biophys Acta 2006;1757:639-47.
19. Maudsley S, Davidson L, Pawson AJ, Chan R, Lopez de Maturana R, Millar RP. Gonadotropin-releasing hormone (GnRH) antagonists promote proapoptotic signaling in peripheral reproductive tumor cells by activating a Gαi-coupling state of the type I GnRH receptor. Cancer Res 2004;64:7533-44.
20. Imai A, Takagi H, Horibe S, Fuseya T, Tamaya T. Coupling of gonadotropin-releasing hormone receptor to Gi protein in human reproductive tract tumors. J Clin Endocrinol Metab 1996;81:3249-53.
21. Limonta P, Moretti RM, Marelli MM, Motta M. The biology of gonadotropin hormone-releasing hormone: role in the control of tumor growth and progression in humans. Front Neuroendocrinol 2003;24:279-95.
22. White CD, Coetsee M, Morgan K, Flanagan CA, Millar RP, Lu ZL. A crucial role for Gαq/11, but not Gαi/o or Gαs, in gonadotropin- releasing hormone receptor-mediated cell growth inhibition. Mol Endocrinol 2008;22:2520-30.
23. Morgan K, Stewart AJ, Miller N, et al. Gonadotropin-releasing hormone receptor levels and cell context affect tumor cell responses to agonist in vitro and in vivo. Cancer Res 2008;68:6331-40.
24. Franke TF, Kaplan DR, Cantley LC. PI3K: down-stream AKTion blocks apoptosis. Cell 1997;88:435-7.
25. Datta SR, Dudek H, Tao X, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997;91:231-41.
26. Mizutani T, Sugihara A, Nakamuro K, Terada N. Suppression of cell proliferation and induction of apoptosis in uterine leiomyoma by gonadotropin-releasing hormone agonist (leuprolide acetate). J Clin Endocrinol Metab 1998;83:1253-5.
27. Bifulco G, Miele C, Pellicano M, et al. Molecular mechanisms involved in GnRH analogue-related apoptosis for uterine leiomyomas. Mol Hum Reprod 2004; 10:43-8.
28. 2-terminal kinase, protein kinase B, extracellular signal-regulated kinase pathways. Cancer Res 2004;64:5736-44.
29. Tanaka Y, Gavrielides MV, Mitsuuchi Y, Fujii T, Kazanietz MG. Protein kinase C promotes apoptosis in LNCaP prostate cancer cells through activation of p38 MAPK and inhibition of the Akt survival pathway. J Biol Chem 2003;278:33753-62.
30. Figueroa C, Tarras S, Taylor J, Vojtek AB. Akt2 negatively regulates assembly of the POSH-MLK-JNK signaling complex. J Biol Chem 2003;278:47922-7.
31. Rose A, Froment P, Perrot V, Quon MJ, LeRoith D, Dupont J. The luteinizing hormone-releasing hormone inhibits the anti-apoptotic activity of insulin-like growth factor-1 in pituitary αT3 cells by protein kinase Cα-mediated negative regulation of Akt. J Biol Chem 2004; 279:52500-16.
32. Kim KY, Choi KC, Park SH, Auersperg N, Leung PC. Extracellular signal-regulated protein kinase, but not c-Jun N-terminal kinase, is activated by type II gonadotropin-releasing hormone involved in the inhibition of ovarian cancer cell proliferation. J Clin Endocrinol Metab 2005;90:1670-7.
33. Kim KY, Choi KC, Auersperg N, Leung PC. Mechanism of gonadotropin- releasing hormone (GnRH)-I and -II-induced cell growth inhibition in ovarian cancer cells: role of the GnRH-I receptor and protein kinase C pathway. Endocr Relat Cancer 2006;13:211-20.
34. Kimura A, Ohmichi M, Kurachi H, et al. Role of mitogen-activated protein kinase/extracellular signal-regulated kinase cascade in gonadotropin-releasing hormone-induced growth inhibition of a human ovarian cancer cell line. Cancer Res 1999;59:5133-42.
35. Emons G, Müller V, Ortmann O, et al. Luteinizing hormone-releasing hormone agonist Triptorelin antagonizes signal transduction and mitogenic activity of epidermal growth factor in human ovarian and endometrial cancer cell lines. Int J Oncol 1996;9:1129-37.
36. 6]GnRH-II inhibits the EGF-induced mitogenic signal transduction in human endometrial and ovarian cancer cells. Int J Oncol 2006;29:1223-9.
37. Chang F, Steelman LS, Shelton JG, et al. Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway [review]. Int J Oncol 2003;22:469-80.
38. Dobkin-Bekman M, Naidich M, Pawson AJ, Millar RP, Seger R, Naor Z. Activation of mitogen-activated protein kinase (MAPK) by GnRH is cell-context dependent. Mol Cell Endocrinol 2006;252:184-90.
39. Neill JD. Mammalian gonadotropin-releasing hormone (GnRH) receptor subtypes. Arch Physiol Biochem 2002;110:129-36.
40. Eicke N, Günthert AR, Viereck V, et al. GnRH-II receptor-like antigenicity in human placenta and in cancers of the human reproductive organs. Eur J Endocrinol 2005;153:605-12.